New gene therapy cures 1st New Yorker of sickle cell anemia
Singapore is using cell therapy to transform its cancer treatments. Doctors say it offers relapsed patients a 50 per cent ...
MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. Find out why.
MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...
A new method is developed to track dormant HIV-infected cells. This breakthrough may lead to new treatments that eliminate ...
In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results